Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
of 8

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global PCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData estimates that the global PCOS therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of the unavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patient satisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility, hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern with the help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants are institutions or universities. Company participation is very low because most of the drugs which are under trial are generics and already being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact the market significantly.Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).ScopeThe report provides information on the key drivers and challenges of the PCOS market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen, Progesterone derivative, Oral contraceptives, Antiobesity drugs and others.- Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt. Ltd. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutics market.- Analysis of key recent licensing and partnership agreements in PCOS market.Reasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global PCOS market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and c
Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Polycystic Ovarian Syndrome (PCOS) Therapeutics - PipelineAssessment and Market Forecasts to 2018Published on November 2011 Report SummaryPolycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, Polycystic Ovarian Syndrome (PCOS) Therapeutics -Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the globalPCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights onthe prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the currentmarket leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. Thisreport is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysisby GlobalDatas team of industry experts.GlobalData estimates that the global PCOS therapeutics market was valued at $656m in 2010, and is expected to grow at a staticCompound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated populationwhich is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steadygrowth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of theunavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patientsatisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility,hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern withthe help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants areinstitutions or universities. Company participation is very low because most of the drugs which are under trial are generics andalready being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact themarket significantly.Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).ScopeThe report provides information on the key drivers and challenges of the PCOS market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010,forecast for eight years to 2018.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen,Progesterone derivative, Oral contraceptives, Antiobesity drugs and others.- Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt.Ltd.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide aqualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for thePolycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!PCOS therapeutics market.- Analysis of key recent licensing and partnership agreements in PCOS market.Reasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and byidentifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global PCOS market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely toimpact the global PCOS market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance ofvarious competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunitiesfor consolidations, investments and strategic partnerships.- Whats the next big thing in the global PCOS market landscape Identify, understand and capitalize. Table of Content1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 62 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Executive Summary 82.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market is Forecast to Show Significant Growth until 2018 82.2 Need for FDA approved products 92.3 Weak pipeline with no disease modifying therapies 103 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Introduction 113.1 Disease Overview 113.2 Epidemiology 113.3 Etiology and Pathology 143.3.1 Androgen Excess 153.3.2 Ovulatory Dysfunction 163.3.3 Insulin Resistance 163.3.4 Obesity and Adipose Tissue Dysfunction 163.3.5 Gonadotropin Abnormalities 163.3.6 Intrauterine Environment 163.3.7 Infancy to Adolescence 163.3.8 Genetics 173.3.9 Environmental Factors 173.4 Signs and Symptoms 183.5 Diagnosis 183.5.1 Careful History and Physical Examination 183.5.2 Laboratory Examination 18Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 2/8
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!3.6 Treatment and Management Pattern 193.6.1 Patient and Family Education 203.6.2 Non-Pharmacological Treatment 213.6.3 Pharmacological Treatment 213.7 Referral Pathway 223.8 GlobalData Pipeline Report Guidance 224 PCOS Therapeutics: Market Characterization 244.1 PCOS Therapeutics Market Size (20052010) Global 244.2 PCOS Therapeutics Market Forecast (20102018) Global 254.3 PCOS Therapeutics Market Size (20052010) The US 264.4 PCOS Therapeutics Market Forecast (20102018) The US 274.5 PCOS Therapeutics Market Size (20052010) France 284.6 PCOS Therapeutics Market Forecast (20102018) France 294.7 PCOS Therapeutics Market Size (20052010) Germany 314.8 PCOS Therapeutics Market Forecast (20102018) Germany 324.9 PCOS Therapeutics Market Size (20052010) Italy 334.10 PCOS Therapeutics Market Forecast (20102018) Italy 344.11 PCOS Therapeutics Market Size (20052010) Spain 354.12 PCOS Therapeutics Market Forecast (20102018) Spain 364.13 PCOS Therapeutics Market Size (20052010) The UK 374.14 PCOS Therapeutics Market Forecast (20102018) The UK 384.15 PCOS Therapeutics Market Size (20052010) Japan 404.16 PCOS Therapeutics Market Forecast (20102018) Japan 414.17 Drivers and Barriers for the PCOS therapeutics market 424.17.1 Drivers for the PCOS therapeutics market 424.17.2 Barriers for the PCOS therapeutics market 424.17.3 Opportunity and Unmet need analysis 434.18 Key Takeaway 445 PCOS Therapeutics: Competitive Assessment 465.1 Overview 465.2 Strategic Competitor Assessment 465.3 Product Profiles for the Major Products in the PCOS Therapeutics Market 475.3.1 Oral contraceptives 475.3.2 Long-acting Gonadotropin-Releasing Hormone (GnRH) analogues 495.3.3 Insulin sensitising agents 505.3.4 Ovulation inducer 515.3.5 Antiandrogens/ Hirsutism treatment 52Spiranolactone 525.4 Key Takeaway 536 PCOS Therapeutics: Pipeline Assessment 546.1 Overview 546.2 Strategic Pipeline Assessment 546.3 PCOS Therapeutics Pipeline Pipeline by Phase of Development 556.3.1 PCOS Therapeutics Phase III Pipeline 556.3.2 PCOS Therapeutics Phase II/III Pipeline 566.3.3 PCOS Therapeutics Phase II Pipeline 566.3.4 PCOS Therapeutics Phase I/II Pipeline 566.3.5 Technology Trends Analytic Framework 56Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 3/8
  • 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!6.4 PCOS Therapeutics Market Pipeline by Mechanism of Action 586.5 PCOS Therapeutics Promising Drugs under Clinical Development 606.6 Molecule Profile for Promising Drugs under Clinical Development 606.6.1 R-TPR-020 606.7 Key Takeaway 607 PCOS Therapeutics: Clinical Trials Mapping 617.1 Clinical Trials by Region/Country (US, EU5 and Japan) 617.2 Clinical Trials by Phase 627.3 Clinical Trials by Trial Status 637.4 Prominent Sponsors 647.5 Top Companies Participating in PCOS Therapeutics Clinical Trials 668 Strategic Assessment 678.1 Key Events Impacting the Future Market 678.2 PCOS Therapeutics: Implications for Future Market Competition 689 PCOS Therapeutics: Future Players 709.1 Introduction 709.2 Company Profiles 719.2.1 Reliance Life Sciences Pvt. Ltd. 7110 PCOS Therapeutics: Licensing and Partnership Deals 7211 PCOS Therapeutics: Appendix 7311.1 Market Definitions 7311.2 Abbreviations 7311.3 Research Methodology 7411.3.1 Coverage 7511.3.2 Secondary Research 7511.3.3 Forecasting 7511.3.4 Primary Research 7711.3.5 Expert Panel Validation 7811.4 Contact Us 7811.5 Disclaimer 7811.6 Bibliography 78List of TablesTable 1: Diagnostic Criteria for PCOS 11Table 2: Common Comorbidity associated with PCOS 12Table 3: Prevalence by Country 14Table 4: Laboratory Tests for the Evaluation of Patients with Suspected PCOS 19Table 5: Commonly used Off-label Drugs 21Table 6: PCOS Therapeutics Market, Global, Revenue ($m), 20052010 25Table 7: PCOS Therapeutics Market, Global, Forecast ($m), 20102018 26Table 8: PCOS Therapeutics Market, the US, Revenue ($m), 20052010 27Table 9: PCOS Therapeutics Market, the US, Forecasts ($m), 20102018 28Table 10: PCOS Therapeutics Market, France, Revenue ($m), 20052010 29Table 11: PCOS Therapeutics Market, France, Forecasts ($m), 20102018 30Table 12: PCOS Therapeutics Market, Germany, Revenue ($m), 20052010 31Table 13: PCOS Therapeutics Market, Germany, Forecasts ($m), 20102018 33Table 14: PCOS Therapeutics Market, Italy, Revenue ($m), 20052010 34Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 4/8
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 15: PCOS Therapeutics Market, Italy, Forecasts ($m), 20102018 35Table 16: PCOS Therapeutics Market, Spain, Revenue ($m), 20052010 36Table 17: PCOS Therapeutics Market, Spain, Forecasts ($m), 20102018 37Table 18: PCOS Therapeutics Market, the UK, Revenue ($m), 20052010 38Table 19: PCOS Therapeutics Market, the UK, Forecasts ($m), 20102018 39Table 20: PCOS Therapeutics Market, Japan, Revenue ($m), 20052010 40Table 21: PCOS Therapeutics Market, Japan, Forecasts ($m), 20102018 42Table 22: PCOS Therapeutics, Phase III Pipeline, 2011 55Table 23: PCOS Therapeutics, Phase II/III Pipeline, 2011 56Table 24: PCOS Therapeutics, Phase II Pipeline, 2011 56Table 25: PCOS Therapeutics, Phase I/II Pipeline, 2011 56Table 26: PCOS Therapeutics Most Promising Drugs under Clinical Development, 2011 60Table 27: PCOS Therapeutics, Clinical Trials by Country, 2011 61Table 28: PCOS Therapeutics - Clinical Trials by Phase, 2011 62Table 29: PCOS Therapeutics, Clinical Trials by Status, 2011 63Table 30: PCOS Therapeutics, Prominent Sponsors, 2011 66Table 31: PCOS Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 66Table 32: Reliance Life Sciences Pvt. Ltd., PCOS Management, Pipeline, 2011 71List of FiguresFigure 1: PCOS Therapeutics Market, Global, Revenue and Forecasts ($m), 20052018 9Figure 2: Opportunity and Unmet Need in the PCOS Therapeutics Market, 2011 10Figure 3: Common Comorbidities Associated with PCOS 12Figure 4: Annual Burden with the Treatment of PCOS in 2004 13Figure 5: Pathophysiology of PCOS 15Figure 6: Signs and Symptoms 18Figure 7: PCOS: Treatment Algorithm 20Figure 8: Referral Pathway 22Figure 9: PCOS Therapeutics Market, Global, Revenue ($m), 20052010 24Figure 10: PCOS Therapeutics Market, Global, Forecast ($m), 20102018 26Figure 11: PCOS Therapeutics Market, the US, Forecast ($m), 20052010 27Figure 12: PCOS Therapeutics Market, the US, Forecast ($m), 20102018 28Figure 13: PCOS Therapeutics Market, France, Revenue ($m), 20052010 29Figure 14: PCOS Therapeutics Market, France, Forecast ($m), 20102018 30Figure 15: PCOS Therapeutics Market, Germany, Revenue ($m), 20052010 31Figure 16: PCOS Therapeutics Market, Germany, Forecast ($m), 20102018 32Figure 17: PCOS Therapeutics Market, Italy, Revenue ($m), 20052010 33Figure 18: PCOS Therapeutics Market, Italy, Forecast ($m), 20102018 35Figure 19: PCOS Therapeutics Market, Spain, Revenue ($m), 20052010 36Figure 20: PCOS Therapeutics Market, Spain, Forecast ($m), 20102018 37Figure 21: PCOS Therapeutics Market, the UK, Revenue ($m), 20052010 38Figure 22: PCOS Therapeutics Market, the UK, Forecast ($m), 20102018 39Figure 23: PCOS Therapeutics Market, Japan, Revenue ($m), 20052010 40Figure 24: PCOS Therapeutics Market, Japan, Forecast ($m), 20102018 41Figure 25: Opportunity and Unmet Need in the PCOS Therapeutics Market, 2011 44Figure 26: PCOS Therapeutics, Strategic Competitor Assessment, 2010 47Figure 27: PCOS Therapeutics Pipeline by Phase of Development, 2011 55Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 5/8
  • 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Figure 28: PCOS Therapeutics, Technology Trends Analytics Framework, 2011 57Figure 29: PCOS Pipeline, Technology Trends Analytics Framework, Description, 2011 58Figure 30: PCOS Therapeutics, Pipeline by Mechanism of Action, 2011 59Figure 31: PCOS Therapeutics, Clinical Trials by Country, 2011 61Figure 32: PCOS Therapeutics, Clinical Trials by Phase (%), 2011 62Figure 33: PCOS Therapeutics, Clinical Trials by Status (%), 2011 63Figure 34: PCOS Therapeutics, Overall Sponsors (%), 2011 64Figure 35: PCOS Therapeutics, Prominent Sponsors (%), 2011 65Figure 36: PCOS Therapeutics Market, Drivers and Restraints, 2011 67Figure 37: Implications for Future Market Competition in the PCOS Market, 2011 68Figure 38: PCOS Therapeutics Market, Pipeline by Company, 2011 70Reliance Life Sciences Pvt. Ltd.Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 6/8
  • 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 3 500.00 Quantity: _____ Site License--USD 7 000.00 Quantity: _____ Corporate License--USD 10 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 7/8
  • 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 8/8

Related Documents